Subsequent studies demonstrated that BME treatment modulates the downstream molecules of c-Met signaling pathway, such as, phosphoStat3, c-myc, and Mcl-1 in HNSCC cells. This evidence concerns the gene MYC and head and neck squamous cell carcinoma.